Reata Pharmaceuticals, Inc.
(NASDAQ : RETA)

( )
RETA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.10%38.410.9%$1248.28m
JNJJohnson & Johnson -0.44%147.950.7%$870.62m
MRKMerck & Co., Inc. -0.06%80.970.7%$637.23m
ABBVAbbVie, Inc. -0.57%92.391.9%$603.09m
BMYBristol-Myers Squibb Co. 1.30%61.811.0%$599.18m
AZNAstraZeneca Plc -0.07%55.371.2%$573.33m
LLYEli Lilly & Co. 0.07%153.031.1%$425.60m
NVSNovartis AG -0.64%82.380.2%$142.36m
GSKGlaxoSmithKline Plc 0.39%40.950.2%$136.09m
MISTMilestone Pharmaceuticals, Inc. -3.27%9.480.0%$135.86m
OPKOPKO Health, Inc. -3.02%5.4611.2%$129.82m
NVONovo Nordisk A/S -0.02%64.630.1%$69.68m
RGENRepligen Corp. -3.25%147.817.1%$68.38m
PRNBPrincipia Biopharma, Inc. -7.86%84.670.0%$58.39m
SNYSanofi -1.17%50.910.2%$56.54m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.